Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
FAQ
- What is Jazz Pharmaceuticals's EBIT?
- Jazz Pharmaceuticals (JAZZ) reported EBIT of $336.6M in Q1 2026.
- How has Jazz Pharmaceuticals's EBIT changed year-over-year?
- Jazz Pharmaceuticals's EBIT increased by 702.1% year-over-year, from -$55.9M to $336.6M.
- What is the long-term trend for Jazz Pharmaceuticals's EBIT?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EBIT has grown at a 61.5% compound annual growth rate (CAGR), from $170.28M to $716.63M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Jazz Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude